SG11201912168TA - Novel substituted xanthine derivatives - Google Patents

Novel substituted xanthine derivatives

Info

Publication number
SG11201912168TA
SG11201912168TA SG11201912168TA SG11201912168TA SG11201912168TA SG 11201912168T A SG11201912168T A SG 11201912168TA SG 11201912168T A SG11201912168T A SG 11201912168TA SG 11201912168T A SG11201912168T A SG 11201912168TA SG 11201912168T A SG11201912168T A SG 11201912168TA
Authority
SG
Singapore
Prior art keywords
novel substituted
xanthine derivatives
substituted xanthine
derivatives
novel
Prior art date
Application number
SG11201912168TA
Inventor
Kai Gerlach
Christian Eickmeier
Achim Sauer
Stefan Just
Bertrand L Chenard
Original Assignee
Boehringer Ingelheim Int
Hydra Biosciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Hydra Biosciences Llc filed Critical Boehringer Ingelheim Int
Publication of SG11201912168TA publication Critical patent/SG11201912168TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201912168TA 2017-07-11 2018-07-06 Novel substituted xanthine derivatives SG11201912168TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180721 2017-07-11
PCT/EP2018/068366 WO2019011802A1 (en) 2017-07-11 2018-07-06 Novel substituted xanthine derivatives

Publications (1)

Publication Number Publication Date
SG11201912168TA true SG11201912168TA (en) 2020-01-30

Family

ID=59325162

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912168TA SG11201912168TA (en) 2017-07-11 2018-07-06 Novel substituted xanthine derivatives

Country Status (30)

Country Link
US (1) US10329292B2 (en)
EP (1) EP3652176B1 (en)
JP (1) JP7114702B2 (en)
KR (1) KR20200030048A (en)
CN (1) CN110997675B (en)
AR (1) AR112448A1 (en)
AU (1) AU2018299824B2 (en)
BR (1) BR112019025611A2 (en)
CA (1) CA3066922A1 (en)
CL (1) CL2020000056A1 (en)
CO (1) CO2019015102A2 (en)
CY (1) CY1125014T1 (en)
DK (1) DK3652176T3 (en)
EA (1) EA039526B1 (en)
ES (1) ES2903268T3 (en)
HR (1) HRP20220029T1 (en)
HU (1) HUE057600T2 (en)
IL (1) IL271799B (en)
LT (1) LT3652176T (en)
MX (1) MX2020000402A (en)
PH (1) PH12020500079A1 (en)
PL (1) PL3652176T3 (en)
PT (1) PT3652176T (en)
RS (1) RS62826B1 (en)
SA (1) SA519410851B1 (en)
SG (1) SG11201912168TA (en)
SI (1) SI3652176T1 (en)
TW (1) TWI801398B (en)
UA (1) UA124793C2 (en)
WO (1) WO2019011802A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3119229A1 (en) * 2018-12-12 2020-06-18 Boehringer Ingelheim International Gmbh Substituted xanthine derivatives
JP7408662B2 (en) * 2018-12-12 2024-01-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Substituted xanthan derivatives
EP4037680A4 (en) * 2019-10-04 2023-10-04 Goldfinch Bio, Inc. Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002234640B8 (en) * 2001-02-24 2009-11-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivative, production and use thereof as a medicament
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
WO2008010073A1 (en) * 2006-07-14 2008-01-24 Pfizer Products Inc. Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine
MX370372B (en) * 2013-03-15 2019-12-11 Hydra Biosciences Inc Substituted xanthines and methods of use thereof.
TWI676626B (en) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 Inhibiting the transient receptor potential a1 ion channel
WO2016023831A1 (en) 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
EP3180340B1 (en) 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
JP6559228B2 (en) 2014-09-17 2019-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Tetrahydroisoquinoline derivatives and pharmaceutical compositions useful for the treatment of obesity and diabetes

Also Published As

Publication number Publication date
TWI801398B (en) 2023-05-11
JP7114702B2 (en) 2022-08-08
CY1125014T1 (en) 2023-03-24
LT3652176T (en) 2022-02-25
HUE057600T2 (en) 2022-05-28
CN110997675A (en) 2020-04-10
AR112448A1 (en) 2019-10-30
HRP20220029T1 (en) 2022-04-15
AU2018299824B2 (en) 2022-06-16
US10329292B2 (en) 2019-06-25
WO2019011802A1 (en) 2019-01-17
MX2020000402A (en) 2020-08-17
CA3066922A1 (en) 2019-01-17
JP2020526591A (en) 2020-08-31
AU2018299824A1 (en) 2019-12-19
IL271799A (en) 2020-02-27
SI3652176T1 (en) 2022-04-29
EA039526B1 (en) 2022-02-07
EP3652176B1 (en) 2021-12-15
CO2019015102A2 (en) 2020-05-15
BR112019025611A2 (en) 2020-06-16
PT3652176T (en) 2022-01-13
PH12020500079A1 (en) 2020-10-05
IL271799B (en) 2022-08-01
UA124793C2 (en) 2021-11-17
US20190016722A1 (en) 2019-01-17
SA519410851B1 (en) 2023-02-26
RS62826B1 (en) 2022-02-28
EA202090270A1 (en) 2020-04-24
CL2020000056A1 (en) 2020-06-12
PL3652176T3 (en) 2022-04-04
KR20200030048A (en) 2020-03-19
EP3652176A1 (en) 2020-05-20
CN110997675B (en) 2022-06-07
ES2903268T3 (en) 2022-03-31
TW201908318A (en) 2019-03-01
DK3652176T3 (en) 2022-01-17

Similar Documents

Publication Publication Date Title
HK1255045A1 (en) Substituted oxopyridine derivatives
IL271607A (en) New azaquinoline derivatives
IL283990A (en) Substituted oxopyridine derivatives
HK1252275A1 (en) Hydroxyalkyl thiadiazole derivatives
IL279938A (en) Spirochromane derivatives
IL271799A (en) Novel substituted xanthine derivatives
PL3359543T3 (en) Cucurbituril derivatives
SI3796975T1 (en) Sulfonylaminobenzamide derivatives
IL271290A (en) Dihydro-pyrrolo-pyridine derivatives
IL283768A (en) Substituted xanthine derivatives
PL3770162T3 (en) Dihydrochromene derivatives
IL265182A (en) Proinsulin derivatives
HK1245796A1 (en) Xanthine derivative
GB201806948D0 (en) Derivatives
PT3319956T (en) Substituted oxopyridine derivatives